Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis

British Journal of Psychiatry

Volumn 180, Issue MAY, 2002, Pages 396-404

  Smith, David ^a   Dempster, Carrie ^a   Glanville, Julie ^a   Freemantle, Nick ^a   Anderson, Ian ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0036261230     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.180.5.396     Document Type: Review

References (29)

1. Comparison of the effects of venlafaxine, desipramine and paroxetine on noradrenalin and methoxamine evoked constriction of the dorsal hand vein
2. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
3. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines
4. Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomised controlled trials
5. Partial remission in depressive disorders
6. Meta-analysis in clinical trials
7. The choice of antidepressants for depression in primary care
8. Selective serotonin reuptake inhibitors: A modest though welcome advance in the treatment of depression
9. Treatment of major depression: Is improvement enough?
10. What is the current place of β-blockade in secondary prevention after myocardial infarction? A systematic overview and meta regression analysis
11. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis
12. SSRIs versus alternative antidepressants for depressive disorders
13. How far are newer antidepressants an advance compared with classical antidepressants?
14. A rating scale for depression
15. The revised monoamine theory of depression: A modulatory role of monoamines, based on new findings from monomaine depletion experiments in humans
16. Venlafaxine. A review of its pharmacology and therapeutic potential in depression
17. Dose-response relationship with venlafaxine
18. A new depression scale designed to be sensitive to change
19. Global mortality, disability, and the contribution of risk factors: Global burden of disease study
20. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
21. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
22. A randomised, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression
23. Combination treatment of noradrenalin and serotonin reuptake inhibitors in resistant depression
24. Bayesian approaches to random-effects meta-analysis: A comparative study
25. Bias in the analysis and reporting of randomized controlled trials
26. Pharmacological profile of antidepressants and related compounds at human monoamine transporters
27. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors